Zobrazeno 1 - 10
of 77
pro vyhledávání: '"Taku, Kikuchi"'
Autor:
Shinya Fujita, Hidenori Kasahara, Jun Kato, Yuya Koda, Kohei Shiroshita, Kentaro Yamaguchi, Mikio Okayama, Ryohei Abe, Taku Kikuchi, Takayuki Shimizu, Takehiko Mori, Keisuke Kataoka, Shinichiro Okamoto
Publikováno v:
Internal Medicine; 2024, Vol. 63 Issue 11, p1549-1562, 14p
Autor:
Taku Kikuchi, Nobuhiro Tsukada, Moe Nomura, Yuki Kasuya, Yuki Oda, Kota Sato, Tomomi Takei, Mizuki Ogura, Yu Abe, Kenshi Suzuki, Tadao Ishida
Publikováno v:
Annals of Hematology. 102:1477-1483
Autor:
Shinya Fujita, Masatoshi Sakurai, Hidenori Kasahara, Jun Kato, Yuya Koda, Kentaro Yamaguchi, Kohei Shiroshita, Mikio Okayama, Ryohei Abe, Taku Kikuchi, Takayuki Shimizu, Takehiko Mori, Keisuke Kataoka, Shinichiro Okamoto
Second- and third-generation (2/3G) tyrosine kinase inhibitors (TKIs) possess excellent treatment effects on chronic myeloid leukemia (CML), and at least one 2/3G TKI is mostly incorporated into the first treatment of CML in all phases. However, the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2d7f3963727f09ecbe84d03b40fc7f25
https://doi.org/10.21203/rs.3.rs-2050971/v1
https://doi.org/10.21203/rs.3.rs-2050971/v1
Autor:
Yuta Yokoyama, Eiji Nozawa, Miho Morita, Emi Ishikawa, Takehiko Mori, Masatoshi Sakurai, Taku Kikuchi, Eri Matsuki, Rie Yamazaki, Keisuke Kataoka, Aya Jibiki, Hitoshi Kawazoe, Sayo Suzuki, Tomonori Nakamura
Publikováno v:
Journal of Clinical Laboratory Analysis. 36
Dasatinib, nilotinib, and bosutinib, second-generation tyrosine kinase inhibitors (TKIs), and ponatinib, a third-generation TKI, are approved pharmaceuticals used in the treatment of chronic myeloid leukemia (CML). Although liquid chromatography-tand
Autor:
Rie Yamazaki, Yohei Tomita, Taku Kikuchi, Miki Koh, Masuho Saburi, Sumiko Kohashi, Yoko Ozawa, Jun Kato, Masatoshi Sakurai, Yuya Koda, Ryohei Abe, Takehiko Mori
Publikováno v:
Bone Marrow Transplantation. 56:1266-1271
Although cytomegalovirus (CMV) remains a leading cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT), the incidence of CMV retinitis is considered to be lower than the incidence of CMV infection in other o
Autor:
Kohei Shiroshita, Yasufumi Masaki, Hidenori Kasahara, Mikio Okayama, Shinichiro Okamoto, Nozomu Kurose, Taku Kikuchi, Takayuki Shimizu, Takahiro Kamiya
Publikováno v:
Internal Medicine
An inguinal lymph node biopsy of a woman with a one-month history of a progressive fever, fatigue, dyspnea, skin rash, and lymphadenopathy revealed a well-preserved basic structure, hyperplastic germinal centers, and an interfollicular region contain
Autor:
Tomoko Arai, Shinya Fujita, Hideaki Nakajima, Hiroshi Kobayashi, Takayuki Shimizu, Daiki Karigane, Tomonori Yaguchi, Naomi Kondoh, Hisako Katagiri, Keiyo Takubo, Rie Yamazaki, Kaori Yahagi, Yoko Yatabe, Shinichiro Okamoto, Masatoshi Sakurai, Mitsuru Murata, Jun Kato, Shinpei Tamaki, Takehiko Mori, Hidenori Kasahara, Maiko Matsushita, Takashi Sasaki, Taeko Hayakawa, Kouhei Shiroshita, Taku Kikuchi, Yutaka Kawakami, Nobuko Shimizu
Publikováno v:
Leukemia & Lymphoma. 62:679-687
Persistence of leukemic stem cells (LSCs) results in the recurrence of chronic myeloid leukemia (CML) after the administration of tyrosine kinase inhibitors (TKIs). Thus, the detection of minimal residual disease (MRD) with LSC potential can improve
Autor:
Shinichiro Okamoto, Hiroki Yokoyama, Masahiro Onoda, Taku Kikuchi, Chikako Ohwada, Yuhei Nagao, Makoto Onizuka, Kunihiko Morita, Emiko Sakaida, Katsuhiro Shono, Jun Kato, Yutaro Hino, Kana Matsumoto, Tatsuzo Mishina, Yuya Koda, Hiroaki Shimizu, Akira Yokota, Yusuke Takeda, Takehiko Mori
Publikováno v:
International Journal of Hematology. 113:128-133
Busulfan (Bu) has been used in combination with fludarabine (Flu; BuFlu) or cyclophosphamide (Cy; BuCy) as conditioning for allogeneic hematopoietic stem cell transplantation (HSCT). This multi-institutional prospective study compared pharmacokinetic
Autor:
Mikio Okayama, Jun Kato, Kota Mizuno, Taku Kikuchi, Masatoshi Sakurai, Takahiro Kamiya, Takehiko Mori, Yuya Koda, Tomohiko Tanigawa
Publikováno v:
Hematology (Amsterdam, Netherlands). 26(1)
This study aimed to evaluate the antiemetic efficacy of a 5-hydroxytryptamine-3 receptor antagonist (5-HT3RA), ondansetron, in patients with malignant lymphoma receiving multi-day cisplatin-based combination chemotherapy.We conducted a single-institu
Autor:
Shohei Mizuno, Akiyoshi Takami, Hiroyuki Takamatsu, Ichiro Hanamura, Yutaka Shimazu, Akira Hangaishi, Nobuhiro Tsukada, Shinichi Kako, Taku Kikuchi, Shuichi Ota, Hiroaki Shimizu, Shinsuke Iida, Satoshi Yoshioka, Masashi Sawa, Takahiro Fukuda, Yoshinobu Kanda, Yoshiko Atsuta, Koji Kawamura
Publikováno v:
Bone marrow transplantation. 57(5)